Investors should keep their eyes on the global nanotechnology market, an arena that was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 34.5% during the forecast period. One emerging NYSE-traded company is standing out in the space as it develops antiviral therapies utilizing nanotechnology. Not long ago the company reported the successful completion of its Phase 1a/1b clinical trial for NV-387, its broad-spectrum antiviral drug. The trial, focusing on COVID-19 treatment, showed no adverse events. This year the company has a focus on advancing NV-387 through further clinical trials, expanding its treatment capabilities to address unmet medical needs. This includes RSV, the flu, and other viruses.
While NV-387 was developed in the context of the COVID-19 pandemic as a broad-spectrum pan-Coronavirus drug, the company has that it has strong antiviral activity against diverse types and families of viruses that include Coronaviruses, RSV, Influenza A, as well as Smallpox/Mpox in relevant animal models of these infections. Thus NV-387 could be the single drug that can combat all of the "tripledemic" viruses - Coronaviruses, RSV, and Influenza, an unmet medical need! Recently the company has found that the antiviral activity of NV-387 against RSV is strong enough to enable lethally infected animals to survive completely and not succumb to the infection.
This message is a PAID ADVERTISEMENT for NanoViricides, Inc. (NYSE American: NNVC) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
No comments:
Post a Comment